Skip to main content

Table 4 Sensitivity analysis

From: Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience

Base case Incremental cost-effectiveness ratio (US$/QALY)
Base case 31,147
Detection benefit from screening
 4 years 34,927
 6 years 27,005
Screening costs
 +20 % 31,636
 −20 % 30,708
Incremental intensified glycemic treatment costs
 +20 % 33,558
 −20 % 28,759
Incremental intensified hypertension treatment costs
 +20 % 31,083
 −20 % 31,234
Complication costs
 +20 % 30,876
 −20 % 31,442
Discount rates applied to costs and QALYs
 1 % 21,281
 10 % 44,424
Utility weights associated with diabetes
 +20 % 26,874
 −20 % 36,977
Effects of intensive glycemic control
 CHD risk reduction: 20 % 15,688
 Stroke risk reduction: 20 % 28,029
 CHD and stroke risk reduction: 20 % 14,769
Scenario Analysis
 Selective screening of screening of hypertensive individuals only 22,695
 Control group not receiving intensive glucose and hypertension treatment 7505